雙成藥業(002693.SZ):擬收購奧拉股份100%股份 9月11日起復牌
格隆匯9月10日丨雙成藥業(002693.SZ)公佈,上市公司擬通過發行股份及支付現金的方式向奧拉投資、Win
Aiming等25名交易對方發行股份及支付現金購買其合計所持有的奧拉股份100%股份並向不超過35名特定投資者募集配套資金。截至本摘要簽署日,標的資產的審計、評估工作尚未完成,本次交易的具體交易價格尚未確定。
本次交易的標的公司主要從事模擬芯片及數模混合芯片的研發、設計和銷售業務,主要產品包括時鐘芯片、電源管理芯片、傳感器芯片、射頻芯片等。本次交易完成後,上市公司將實現戰略轉型,重點發展模擬芯片及數模混合芯片設計業務,有利於上市公司尋求新的利潤增長點,進一步提高上市公司持續經營能力。
根據深圳證券交易所的有關規定,經公司申請,上市公司股票(證券簡稱:雙成藥業,證券代碼:002693)將於2024年9月11日(星期三)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.